Propella selects new drug opportunities in the context of unmet patient needs. Our proprietary approach to the design and development of improved therapies aims to bring improved choices to patients and healthcare professionals underserved by current standards of care.
bright light thinking
We accomplish our mission by thoroughly investigating and then re-designing active pharmaceutical ingredients to apply our lymphatic targeting approach thereby yielding superior therapies. Once a candidate is identified, we assess all aspects of its profile, including the applicability of lymphatic targeting for both molecule and indication, unmet medical needs, barriers to entry, and commercial opportunities. We then engage stakeholders such as patients, doctors, payers and other experts for insight and validation of a new this novel therapeutic.
The lymphatic system is a vast network of vessels, lymph nodes and organs that connects the circulatory and immune systems. Lymphatic targeting employs the lymphatic system to preferentially deliver therapeutic concentrations of drug to target tissues. Lymphatic targeting has shown promise across different routes of administration, including by intramuscular injection and oral administration. Advantages of lymphatic targeting include:
- Increased bioavailability and pharmacodynamic activity
- Creation of secondary drug depots in key target tissues including lymph nodes and bone metastatic sites
- Reduced drug delivery to organs causing toxicity (e.g., liver, CNS)
- Improved safety margin/therapeutic index
The active ingredients in our products have been well studied previously and our drug product candidates are protected by composition of matter patents owned by us, which provides for a risk-mitigated development and commercialization path. We believe making new drugs that are more effective, tolerable, and convenient for patients is both smart science and great business. Brighter treatments lay ahead.